Results 141 to 150 of about 5,907 (191)
Some of the next articles are maybe not open access.
Acid Alpha-Glucosidase from Human Heart
Enzyme, 1983An alpha-glucosidase maximally active at acid pH has been purified from human heart some 2,600-fold and its properties compared to a purified alpha-glucosidase from human liver. Molecular weight was evaluated using three different analytical procedures. The effect of various cations was determined.
J P, Chambers, J C, Williams
openaire +2 more sources
Identity of alpha-glucosidase of human kidney with urine F-1 alpha-glucosidase.
Journal of biochemistry, 1982alpha-Glucosidase was extracted from a homogenate of human kidney, initially with 0.02 M Tris-HCl buffer, pH 7.6, and subsequently with a mixture of 0.5% cholate and 0.5% Triton X-100 in the same buffer, pH 7.6. The enzyme in each of these two fractions was purified to the electrophoretically pure state by fractional precipitation with ammonium sulfate,
N, Minamiura +3 more
openaire +2 more sources
Drugs of the Future, 2003
Pompe's disease or glycogen storage disease type II is an inherited progressive skeletal muscle disorder caused by deficiency of the lysosomal enzyme α-glucosidase. The most severe form of the disease affects infants and results in feeding difficulties, respiratory and cardiac problems and motor delay.
openaire +1 more source
Pompe's disease or glycogen storage disease type II is an inherited progressive skeletal muscle disorder caused by deficiency of the lysosomal enzyme α-glucosidase. The most severe form of the disease affects infants and results in feeding difficulties, respiratory and cardiac problems and motor delay.
openaire +1 more source
[alpha-Glucosidase inhibitor].
Nihon rinsho. Japanese journal of clinical medicine, 1999Oral anti-diabetic agents with hypoglycemic action via mechanisms distinct from the sulfonylureas have recently been developed. One of these, alpha-glucosidase inhibitor slows the absorption rate of carbohydrate from the small intestine. Effects of voglibose on glycemic control and on the function of pancreatic islets were evaluated using Goto-Kakizaki
openaire +1 more source
[Alpha-glucosidase inhibitor].
Nihon rinsho. Japanese journal of clinical medicine, 2015Alpha-glucosidase inhibitors (α-GI) have abdominal signs which are generally regarded as side-reaction. The abdominal signs are caused by generation of intestinal gas which contains hydrogen gas. The hydrogen gas absorbed in the body eliminates oxidant stress and consequently the abdominal signs may have beneficial effects preventing onset and ...
openaire +1 more source
alpha-Glucosidase deficiency (Pompe's disease).
Enzyme, 1987alpha-Glucosidase is deficient (less than 30% of control) in Pompe's disease, but the extent of the deficiency does not always correlate with the severity of the clinical symptoms. The defects that lead to a deficiency of alpha-glucosidase include synthesis of catalytically inactive protein, absence of mRNA for the enzyme, decreased synthesis of the ...
Tager, J. M. +6 more
openaire +2 more sources
Fermentation of Saccharose by Alpha-Glucosidase
Nature, 1962I HAVE isolated two melibiose-fermenting yeasts, Saccharomyces oleaginosus1 and S. hienipiensis2, which, by means of Wickerham's method3, are capable of fermenting maltose, but which neither ferment nor assimilate saccharose. With the Delft method (Kreger-van Rij, N. J. W., private communication), slow fermentation of the saccharose was obtained.
openaire +2 more sources
Les inhibiteurs des alpha-glucosidases
Actualités Pharmaceutiques, 2017Resume L’arsenal therapeutique permettant la prise en charge du diabete evolue regulierement. Cependant, d’anciennes classes sont toujours sur le marche, meme si elles sont parfois caracterisees par une efficacite modeste comme les inhibiteurs des alpha-glucosidases.
openaire +1 more source
alpha-glucosidase (CHO) (Genzyme).
Current opinion in investigational drugs (London, England : 2000), 2005Genzyme General is developing recombinant human alpha-glucosidase, produced in mammalian cell culture, as a potential treatment for Pompe disease. By July 2004, enrollment was completed in two clinical trials and an observational study in adults. Genzyme was planning to file for regulatory approval in Europe during 2004, followed by filings in the US ...
openaire +1 more source